Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2012 3
2013 6
2014 5
2015 7
2016 5
2017 4
2018 2
2019 7
2020 7
2021 9
2022 17
2023 10
2024 11
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.
Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, Brooks L, Caldwell JM, Fjällbrant H, Grindebacke H, Ho CN, Keith M, McCrae C, Sinibaldi D, White WI, Datto CJ; MESSINA Trial Investigators. Rothenberg ME, et al. N Engl J Med. 2024 Jun 27;390(24):2252-2263. doi: 10.1056/NEJMoa2313318. N Engl J Med. 2024. PMID: 38924732 Clinical Trial.
Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations.
Arnim UV, Biedermann L, Aceves SS, Bonis PA, Collins MH, Dellon ES, Furuta GT, Gonsalves N, Gupta S, Hirano I, Lucendo AJ, Miehlke S, Oliva S, Schlag C, Schoepfer A, Straumann A, Vieth M, Bredenoord AJ; EUREOS and TIGERs. Arnim UV, et al. Among authors: schlag c. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2526-2533. doi: 10.1016/j.cgh.2022.12.018. Epub 2022 Dec 24. Clin Gastroenterol Hepatol. 2023. PMID: 36572109 Free article.
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.
Bredenoord AJ, Dellon ES, Schlag C, Cianferoni A, Xia C, Pela T, Durrani S, Radwan A, Jacob-Nara JA. Bredenoord AJ, et al. Among authors: schlag c. Expert Rev Gastroenterol Hepatol. 2025 Jan-Feb;19(2):197-209. doi: 10.1080/17474124.2025.2461516. Epub 2025 Feb 5. Expert Rev Gastroenterol Hepatol. 2025. PMID: 39909733 Free article. Clinical Trial.
Dilation in EoE: Still Necessary?
Schlag C. Schlag C. Inflamm Intest Dis. 2025 Jun 30;10(1):187-192. doi: 10.1159/000546290. eCollection 2025 Jan-Dec. Inflamm Intest Dis. 2025. PMID: 40678702 Free PMC article. Review.
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
Bredenoord AJ, Dellon ES, Hirano I, Lucendo AJ, Schlag C, Sun X, Glotfelty L, Mannent L, Maloney J, Laws E, Mortensen E, Shabbir A. Bredenoord AJ, et al. Among authors: schlag c. Gut. 2024 Feb 23;73(3):398-406. doi: 10.1136/gutjnl-2023-330220. Gut. 2024. PMID: 38050037 Free PMC article. Clinical Trial.
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study.
Biedermann L, Schlag C, Straumann A, Lucendo AJ, Miehlke S, Vieth M, Santander C, Ciriza de Los Rios C, Schmöcker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Halstead M, Pfurr S, Mueller R, Schoepfer AM, Attwood S; International EOS-2 Study Group. Biedermann L, et al. Among authors: schlag c. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2144-2154.e6. doi: 10.1016/j.cgh.2024.10.034. Epub 2024 Dec 16. Clin Gastroenterol Hepatol. 2025. PMID: 39694205 Free article. Clinical Trial.
91 results